Patisiran
Products Patisiran is marketed as a concentrate for the preparation of an [infusion solution>infusion] (Onpattro). It was approved in the US and EU in 2018 and in many countries in 2019. Structure and properties Patisiran belongs to the small interfering RNA (siRNA) group of drugs. It is a small, double-stranded ribonucleic acid. The active ingredient … Patisiran
